FDA warned CAMA Wellness Center/IodoRios that its IoWipe hand wipe was an unapproved, misbranded drug with COVID-19 prevention claims.
What happened
FDA reviewed www.cp.camacenter.com on February 8, 2021, and FTC reviewed the site on March 2, 2021; a related Facebook page directed consumers to the site. FDA found the website offered an iodine-based reusable hand wipe, IoWipe, with claims that it could prevent, treat, or destroy COVID-19. The letter cites package-insert and website/social-media statements as evidence the product was intended as an unapproved new drug and was misbranded.
What FDA found
The hand wipe is an unapproved new drug because the company intended it to prevent or treat COVID-19 without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The product is misbranded because its labeling and website claims misleadingly present it as safe or effective for COVID-19.
section 502 of the FD&C Act, 21 U.S.C. § 352The company is prohibited from introducing or delivering the product into interstate commerce.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertised that the product can prevent, treat, or cure disease without competent and reliable scientific evidence, including for COVID-19.
FTC Act, 15 U.S.C. 41 et seq.
What FDA wants
FDA tells the company to immediately stop selling unapproved and unauthorized COVID-19 products and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken, how it will prevent recurrence, and supporting documents. FTC separately asks for an email within 48 hours to Richard Cleland describing actions taken.
Who should pay attention
- retailers and online marketplaces selling hand wipes
- companies making COVID-19 prevention claims
- brands using websites and social media for sanitizer claims
This is a summary. Read the original letter on fda.gov.